Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eisai and Johns Hopkins Extend Drug Discovery Collaboration

By Eisai Inc. | June 2, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced that they have extended their drug discovery collaboration through an exclusive licensing agreement.

The agreement is for a license of compounds identified from collaborative research between Eisai’s Andover Innovative Medicines (AiM) Institute in Andover, MA, and Johns Hopkins Drug Discovery (JHDD).

The compounds were the outcome of research carried out in the laboratory of Professor Barbara Slusher Ph.D., MAS, professor of neurology, neuroscience, psychiatry, medicine and oncology at Johns Hopkins and the director of JHDD, and is part of a broader ongoing collaborative research arrangement between Eisai and Johns Hopkins that is designed to translate new target discoveries into novel small molecule therapeutics for the development of medicines for neurology and oncology.

Eisai has licensed these select small molecule compounds and intellectual property for further research, development and commercialization at its AiM Institute. In return, Johns Hopkins will receive a one-time upfront payment of $500,000 for license consideration, as well as potential future milestones and royalties upon the successful commercialization of a product based on these compounds.

“This collaboration with Professor Slusher and her group was designed to fast track the development of medicines on innovative targets outside of our internal research portfolio,” said Fiona Randall, Ph.D., who is the external alliance manager at Eisai AiM Institute and leads the collaboration. “We are delighted to announce this first in-licensing success which marks an important milestone in our partnership, and as a reflection of Eisai’s belief in more positive outcomes we have also committed an additional $500,000 in general research support to the lab.” 

In 2011, Eisai and Johns Hopkins formalized the initial joint drug discovery collaboration. Under the terms of that agreement, Johns Hopkins Drug Discovery, led by Professor Slusher, provided Eisai with novel therapeutic targets.

For the targets of interest, screening assays were developed and validated by the Johns Hopkins Drug Discovery team, and then transferred to Eisai who utilized the Johns Hopkins assay to conduct high-throughput screening of its proprietary compound library collection to identify compounds that interact with the targets. Utilizing hybrid industry-academic drug discovery teams, the newly identified screening compounds were then subject to extensive structure-activity relationship studies and characterization in preclinical models to identify lead compounds for potential clinical development.

“By combining Johns Hopkins’ unique drug targets and screening assays with Eisai’s diverse and rich chemical libraries, our integrated project teams worked together seamlessly to successfully identify clinical lead compounds for development,” Slusher said. “The success in this approach serves as a model for future pharma-academic collaborations.” 

The Johns Hopkins Drug Discovery Program consists of a multidisciplinary team of scientists with industrial experience and core expertise in drug discovery research, including medicinal chemistry, screening assay development, drug metabolism and pharmacokinetics, and animal pharmacology/toxicology. 

“We are excited to continue our work with Professor Slusher and her drug discovery team at Johns Hopkins,” said Dr. Takashi Owa, chief clinical officer and chief medical officer of Eisai’s Oncology Business Group. “This collaboration continues to build momentum, and we look forward to moving this specific project towards a real benefit for patients with cancer.”

(Source: PR Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE